October 2025, Guatemala City – The iconic Tea House at La Aurora Zoo was the setting for the launch of the new antiparasitic that is revolutionizing the pet market: Atrevia® 360°, a next-generation oral ecto-endoparasitic that sets a new standard in comprehensive protection for dogs.
Petmedica, together with Monteco S.A., its strategic partner in Guatemala, held the official launch in the country with a large turnout of over 200 attendees, including veterinarians, veterinary clinic owners, and animal health professionals.
Dr. Luis Alfredo Chávez Balarezo, Petmedica's Technical Sales Manager, was responsible for presenting the main attributes and mechanism of action of Atrevia® 360°, generating great interest among attendees due to its efficacy and convenience. The unique combination of three active ingredients—fluralaner, moxidectin, and praziquantel—is patent-pending and provides up to three months of long-lasting protection against fleas, ticks, and mites, with added protection against tapeworms and heartworms. The SmartCap® technology in its formulation ensures excellent palatability.
Atrevia® 360°'s innovation has been recognized internationally with the 2025 Pet Innovation Award in the Preventative Pet Care category, an award presented in the United States, validating its innovation and impact on animal welfare.
Petmedica thanks the Guatemalan veterinary community for its warm reception and reaffirms its commitment to continue developing and delivering innovative veterinary solutions that improve the quality of life for pets.
To learn more about the complete Atrevia line, visit www.atrevia.vet.
